Table 3 Cost-effectiveness analysis results (main analysis)
Outcome | Sample size | ∆C (95%CI) | ∆E (95%CI) | ICER | Distribution CE-plane (%) | ||||
|---|---|---|---|---|---|---|---|---|---|
Comparison 1 (UC + MI vs. UC) | |||||||||
UC + MI | UC | EUR | Points | NOK/point | NE | SE | SW | NW | |
QALYs (0–1) | 169 | 171 | -2580 (-5687 to 612) | -0.001 (-0.02 to 0.01) | 1756221 | 1.1 | 40.8 | 53.9 | 4.2 |
Sickness absence days reduction over six months | 169 | 171 | -538 (-1358 to 352) | 5.08 (-3.3 to 13.5) | -106 | 8.5 | 79.1 | 10.0 | 2.1 |
Comparison 2 (UC + SVAI vs. UC) | |||||||||
UC + SVAI | UC | EUR | Points | NOK/point | NE | SE | SW | NW | |
QALYs (0–1) | 169 | 171 | -2899 (-5840 to 18) | -0.002 (-0.02 to 0.01) | 1553061 | 0.5 | 39.9 | 57.5 | 2.1 |
Sickness absence days reduction over six months | 169 | 171 | -695 (-1459 to -3) | 7.9 (-0.04 to 15.9) | -88 | 2.6 | 94.8 | 2.4 | 0.2 |